pembrolizumab,vibostolimab,favezelimab
merck
['gu ', 'mibc', 'pembro', 'key,note,57', 'nmibc']
keynote 057 cohort b results at asco gu 2023. pembro mono for pts with high risk nmibc unresponsive to bcg shows impressive efficacy. 
A dedicated conference for oncology held under the theme "Access. Educate. Collaborate"